News
Datroway filed for TNBC in EU after data delay
Daiichi Sankyo and AstraZeneca have filed their first marketing application for TROP2-targeting Datroway in triple-negative breast cancer.
News
MSD claims two national priority vouchers; report
The next two discretionary priority vouchers to be awarded by the FDA are reported to be heading for two MSD drug candidates.
News
As year-end nears, pharma groups plump up their pipelines
Bristol Myers Squibb, Sanofi, Pfizer, Roche, and Yarrow Bioscience all added to their pipelines this week in an end-of-year licensing deal flurry.
News
Padcev/Keytruda scores again in early bladder cancer
Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as perioperative therapy for muscle-invasive bladder cancer.
Oncology
ESMO25: Perspective on ‘inside-out oncology’ and targeted al...
Perspective Therapeutics is advancing image‑guided, targeted alpha‑particle therapies (TATs). We spoke to Thijs Spoor at ESMO 2025 to find out more.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
